As cancer diagnoses go, prostate cancer is often a less serious one.
Prostate cancer is frequently slow-growing and slow to spread. For many men, prostate cancer is less serious than their other medical conditions. For these reasons, and possibly because of earlier detection of low-grade prostate cancers,
prostate cancer has one of the highest survival rates of any type of cancer. WebMD takes a look at prostate cancer survival rates and what they mean to you. After skin cancer, prostate cancer is the most common cancer in men. About 1 in 7 men will be diagnosed with prostate cancer in their lifetime. And these are just the men who are diagnosed. Among very elderly men dying of other causes, a
surprising two-thirds may have prostate cancer that was never diagnosed. Only 1 in 36 men, though, actually dies from prostate cancer. That's because most prostate cancers are diagnosed in older men in whom the disease is more likely to be slow-growing and non-aggressive. The majority of these men eventually pass away from heart disease,
stroke, or other causes -- not their prostate cancer. Thinking about survival rates for prostate cancer takes a little mental stretching. Keep in mind that most men are around 70 when diagnosed
with prostate cancer. Over, say, five years, many of these men will die from other medical problems unrelated to prostate cancer. To determine the prostate cancer survival rate, these men are subtracted out of the calculations. Counting only the men who are left provides what's called the relative survival rate for prostate cancer. Taking that into consideration, the relative survival rates for most kinds of prostate cancer are actually pretty good. Remember, we're not counting men
with prostate cancer who die of other causes: Many men with prostate cancer actually will live much longer than five years after diagnosis. What about longer-term survival rates? According to the American Society of Clinical Oncology, for men with local or regional prostate cancer: As with all cancers, doctors use the term stage to describe the characteristics of the primary tumor itself, such as its size and how far prostate cancer has spread when it is found. Staging systems are complicated. The staging system for most cancers, including prostate cancer, uses three different aspects of tumor growth and spread. It's called the TNM system, for tumor, nodes, and metastasis: Using the TNM system, each man's prostate cancer can be described in detail and compared to other men's prostate cancer. Doctors use this information for studies and to decide on treatments. As far as survival rates for prostate cancer go, however, the staging system is pretty simple. As we've mentioned, in terms of survival rates, men with prostate
cancer can be divided into two groups: How is prostate cancer staged?Microscopic-level image of prostate cancer cells. Prostate cancer is one of the most common types of cancer that develops in men and is the second leading cause of cancer deaths in American men, behind lung cancer and just ahead of colorectal cancer. The prognosis for prostate cancer, as with any cancer, depends on how advanced the cancer has become, according to established stage designations. The prostate gland is a walnut-sized gland present only in men, found in the pelvis below the bladder. The prostate gland wraps around the urethra (the tube through which urine exits the body) and lies in front of the rectum. The prostate gland secretes part of the liquid portion of the semen, or seminal fluid, which carries sperm made by the testes. The fluid is essential to reproduction. The term to stage a cancer means to describe the evident extent of the cancer in the body at the time that the cancer is first diagnosed.
Prostate cancer is comprised nearly always of adenocarcinoma cells -- cells that arise from glandular tissue. Cancer cells are named according to the organ in which they originate no matter where in the body we find such cells.
What are the stages of prostate cancer?Cancer staging is first described using what is called a TNM system. The "T" refers to a description of the size or extent of the primary, or original, tumor. "N" describes the presence or absence of, and extent of spread of cancer to lymph nodes that may be nearby or further from the original tumor. "M" describes the presence or absence of metastases -- usually distant areas elsewhere in the body other than regional (nearby) lymph nodes to which cancer has spread. Cancers with specific TNM characteristics are then grouped into stages, and the stages are then assigned Roman numerals with the numerals used in increasing order as the extent of the cancer being staged increases or the cancer prognosis worsens. Prognosis is finally reflected by considering the patient's PSA score at presentation as well as their Gleason score (the grading system used to determine the aggressiveness of prostate cancer) in assigning a final stage designation. The American Joint Commission on Cancer (AJCC) system for prostate cancer staging is as follows: The primary tumor (T)
Traditionally, advanced prostate cancer was defined as a disease that had widely metastasized beyond the prostate, the surrounding tissue, and the pelvic lymph nodes and was incurable. However, a more contemporary definition includes patients with the lower-grade disease with an increased risk of progression and/or death from prostate cancer in addition to those with widely metastatic disease. The National Cancer Institute and the National Comprehensive Cancer Network (NCCN) guidelines on prostate cancer version 2.2017 indicate the following: CT scan is used for the initial staging in select patients including
Bone scan is recommended in the initial evaluation of patients at high risk for skeletal metastases including
The regional lymph nodes (N) N designations refer to the presence or absence of prostate cancer in nearby lymph nodes, including what is referred to as the hypogastric, obturator, internal and external iliac, and sacral nodes.
The distant metastasis (M) M designations refer to the presence or absence of prostate cancer cells in distant lymph nodes or other organs. Prostate cancer that has spread through the bloodstream most often first spreads into the bones, then into the lungs and liver.
IMAGESProstate Illustrion Browse through our medical image collection to see illustrations of human anatomy and physiology See ImagesStratifying prostate cancer by riskThe NCCN guidelines stratify prostate cancer by risk. The risk groups are based on the staging of prostate cancer, the Gleason score, PSA, and the number and extent of biopsy cores positive for cancer. The risk stratification may help decide what treatment option is best for each individual.
Health NewsWhat are prostate cancer survival rates by stage?Staging evaluation is essential for the planning of treatment for prostate cancer.
Prognosis refers to the likelihood that cancer can be cured by treatment, and what the patient's life expectancy is likely to be as a consequence of having had a prostate cancer diagnosis. If cancer is cured, your life expectancy is what it would have been had you never been diagnosed with prostate cancer. If cancer cannot be cured due to it recurring in distant locations as metastases, or recurs either locally (where it started) or in an area no longer able to be treated in a curative manner, then estimates can be made of what is likely to be your survival-based again on group statistics for people who have been in the same situation. Nomograms are charts or computer-based tools that use complex math from the analysis of many patients' treatment results.
The prognosis for prostate cancer varies widely and depends on many factors, including the age and health of the patient, the stage of the tumor when it was diagnosed, the aggressiveness of the tumor, and cancer's responsiveness to treatment, among other factors.
IMAGESProstate Illustrion Browse through our medical image collection to see illustrations of human anatomy and physiology See Images
Coping with prostate cancerThe diagnosis of cancer can cause great anxiety to the individual and his family and friends. At times, one may have troubles coping with the diagnosis, the disease, and its treatment. Searching online for information may prove overwhelming also and may not be the best resource. Ask your physician or local hospital about local resources. Often, there are local prostate cancer support groups which may help you cope with your feelings and provide local resources for more knowledge. You may consider contacting one or more of the following organizations:
The Internet has provided access to a number of sites focusing on prostate cancer treatment and outcomes. The National Cancer Institute and the National Comprehensive Cancer Network (NCCN) have patient information, as well as the American Urological Association. Subscribe to MedicineNet's Cancer Report NewsletterBy clicking "Submit," I agree to the MedicineNet Terms and Conditions and Privacy Policy. I also agree to receive emails from MedicineNet and I understand that I may opt out of MedicineNet subscriptions at any time. Medically Reviewed on 11/16/2021 References Ahlering, T., et al. "Unintended consequences of decreased PSA-based prostate cancer screening." World J Urol 37.3 March 2019: 489-496. American Cancer Society (ACS). <http://www.cancer.org/cancer/prostatecancer/index>. American Urological Association. "Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline." 2017. <http://www.auanet.org/guidelines/clinically-localized-prostate-cancer-new-(aua/astro/suo-guideline-2017)>. Byrd, E.S., et al. AJCC Cancer Staging Manual, 7th Ed. New York, NY: Springer, 2009. The James Buchanan Brady Urological Institute. Johns Hopkins Medicine. Lu-Yao, G.L., P.C. Albertson, D.F. Moore, et al. "Fifteen-year outcomes following conservative management among men aged 65 years or older with localized prostate cancer." Eur Urol 68.5 (2015): 805-811. Mottet, Nicolas, et al. "Updated Guidelines for Metastatic Hormone-Sensitive Prostate Cancer: Abiraterone Acetate Combined With Castration Is Another Standard." European Urology 73 (2018): 316-321. National Comprehensive Cancer Network "Prostate Cancer." Memorial Sloan Kettering Cancer Center. https://www.cancer.net/cancer-types/prostate-cancer/statistics What is the life expectancy with a Gleason score of 10?Maximum estimated lost life expectancy for men with Gleason score 5 to 7 tumors was 4 to 5 years and for men with Gleason score 8 to 10 tumors was 6 to 8 years. Tumor histologic findings and patient comorbidities were powerful independent predictors of survival.
Can a man live 10 years with metastatic prostate cancer?Survival for all stages of prostate cancer
more than 95 out of 100 (more than 95%) will survive their cancer for 1 year or more. more than 85 out of 100 (more than 85%) will survive their cancer for 5 years or more. almost 80 out of 100 (almost 80%) will survive their cancer for 10 years or more.
How long can a man live with metastatic prostate cancer?A decade ago, a man with metastatic prostate cancer would typically have a life expectancy of two to three years. Today, life expectancy for men with the same advanced disease is likely to be five to six years.
What is the survival rate for Stage 4 metastatic prostate cancer?Stage IV Prostate Cancer Prognosis
Prostate cancers detected at the distant stage have an average five-year survival rate of 28 percent, which is much lower than local and regional cancers of the prostate.
|